Kornimate/medical-research-clean huggingface dataset:
a prospective, single-arm, multi-centre, blinded, observational, diagnostic accuracy study with a diagnostic medical product

Conditions: Thyroid

Summary: after thyroid surgery, 0.6 to 4% of patients develop postoperative bleeding. 90% of this postoperative bleeding occurs within the first 48 hours. most of the time, the complications are rapidly progressing and require immediate attention. up to 0.6% of patients with postoperative bleeding die. in a clinical study with postoperative pressure measurements it could be shown that postoperative bleeding without interruption leads to a continuous increase in pressure in the neck, as is observed when coughing and pressing. systematic invasive pressure measurement in the thyroid compartment after surgery might detect a continuous increase in pressure which is often caused by a growing haematoma, indicating serious post-surgery bleeding at a much earlier time compared to state of the art diagnostic workflow. n routine clinical care, detection of serious haemorrhage depends on the patients alerting symptoms even if post-operative intermittent monitoring of vital parameters and wound conditions is performed according to current medical guidelines and local instructions. device-based, continuous haemorrhage detection within 36 to 48 hours after surgery would allow to objectively measure an increase in cervical pressure before symptoms occur, i.e. early detection of risk leading to timely therapeutic actions. thus, the risk of serious complications like hypoxic brain damage and death caused by post-operative haemorrhage is minimized. in addition, the intervention team would be able to fine-tune necessary actions during the rescue procedure based on objective pressure values, e.g. the decision to open cutaneous sutures immediately or later in the operation theatre, and therefore reduce additional perioperative morbidity and increase patients' safety.


Eligibility criteria:
inclusion criteria: * age ≥18 years. * indication for thyroid surgery (e.g. total thyroidectomy, subtotal resection, partial resection or lobectomy) in routine clinical care according to applicable medical guidelines using all adequate surgical approaches. * signed informed consent exclusion criteria: - intended use of drains
efficacy of hifu-ar on blood loss reduction in patients with liver metastases requiring hepatectomy

Conditions: Liver Metastasis

Summary: the purpose of this study is to evaluate whether hifu-assisted liver resection (hifu-ar) results in reduced blood loss compared to standard liver resection in patients with lm.this is a prospective, monocentric, randomized (1:1 ratio), comparative, open-label phase ii study.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years at the day of consenting to the study. * patients with liver metastases requiring a hepatectomy for ≥ 2 segments. * ecog ps ≤ 1. * adequate bone marrow and liver function at baseline as defined below: * platelet count ≥ 100 x 109/l, and hemoglobin of ≥ 9 g/dl), * total bilirubin ≤ 1.5 x uln, ast and alt ≤ 5 x uln. * recovered from prior anti-neoplasic treatment-related toxicity (grade \<2 persistent treatment-related toxicity as per ctcae v4 are accepted). * willingness for follow-up visits. * covered by a medical insurance. * signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment. exclusion criteria: * patients having previously undergone * a major hepatic surgery (i.e. more than 3 liver segments) or * biliary major surgery. * patient with cirrhosis or sinusoidal obstruction syndrome with portal hypertension. * pregnant women (women of childbearing potential are required to have a negative pregnancy test within 72 hours prior to inclusion). a positive urine test must be confirmed by a serum pregnancy test.

Keywords: hepatectomy liver metastasis high-intensity focused ultrasound liver metastases (lm) requiring surgery
a study of du-176b, prevention of venous thromboembolism in patients after total hip arthroplasty

Conditions: Prevention; Venous Thromboembolism

Summary: the objective of this study is to assess the efficacy and safety of du-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.


Eligibility criteria:
inclusion criteria: * patients undergoing unilateral total hip arthroplasty exclusion criteria: * subjects with risks of hemorrhage * subjects with thromboembolic risks * subjects who weigh less than 40 kg * subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant

Keywords: anticoagulants venous thromboembolism thromboembolism thrombosis enoxaparin sodium embolism deep vein thrombosis du-176b edoxaban factor xa total hip arthroplasty
a study to evaluate the use of memantine in combination with anti-hiv drugs to treat aids dementia complex (adc)

Conditions: AIDS Dementia Complex; HIV Infections

Summary: the purpose of this study is to determine the safety and effectiveness of memantine, an experimental drug, in improving aids dementia complex (adc). the symptoms of adc can be improved with zidovudine (zdv). however, zdv therapy has been associated with significant toxicities, and the effectiveness of zdv seems to decrease during the second and third years of therapy. the effectiveness of other antiretroviral drugs as treatment for adc is not known, so it is important to explore alternative therapies.

the signs and symptoms of the aids dementia complex can be alleviated by zidovudine (zdv). however, zdv therapy has been associated with significant toxicities, particularly bone marrow suppression. the efficacy of zdv appears to decrease during the second and third years of therapy. it is not known whether this reflects cumulative toxicity. in addition, the efficacy of other antiretroviral agents remains uncertain. hence, adjunctive therapy for cognitive and motor symptoms of aids is important. patients will be randomized to one of the following 2 arms: arm 1 receives memantine plus concurrent antiretroviral therapy; arm 2 receives placebo plus concurrent antiretroviral therapy. the initial dose of memantine is increased each week for the next 3 weeks, unless a maximum tolerated dose is reached. following a 16-week evaluation period there is a 4-week washout prior to re-assessment. after the washout period, all patients, including those formerly randomized to the placebo arm, are given the opportunity to receive an open-label, 12-week administration of memantine. \[as per amendment 4/6/99: the open-label phase is extended by 48 weeks to a total of 60 weeks of therapy. patients who did not receive the initial 12 weeks of open-label treatment are eligible still for the 48-week open-label treatment phase.\]

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv positive. * have been diagnosed with aids dementia complex (adc). * have an estimated iq of at least 70 (before the onset of adc) or the ability to read at a 6th grade level. * have impaired mental skills. * are age18 or older. exclusion criteria you will not be eligible for this study if you: * have a history of a neurologic disease unrelated to hiv infection. * have a history of chronic seizures or head injuries. * have a history of central nervous system infections. * have certain cancers. * have any psychiatric illness. * have an active aids-defining opportunistic infection. * are pregnant or breast-feeding.

Keywords: drug therapy, combination administration, oral aids dementia complex zidovudine anti-hiv agents memantine
establish diagnostic models based on olfactory function and odor-induced brain activation for diabetes-related cognitive impairment

Conditions: Type 2 Diabetes Mellitus; Cognitive Impairment

Summary: this is a cross-sectional and longitudinal study to establish diagnostic models based on olfactory function assessments and odor-induced brain activation for cognitive impairment in patients with type 2 diabetes mellitus.

patients with diabetes have increased risks of cognitive impairment and dementia, which affecting the quality of life and diabetes management. therefore, it is an urgent challenge to identify non-invasive biomarkers for early diagnosis and prognosis of the cognitive decline in patients with diabetes. previous research has shown that both olfactory dysfunction and decreased odor-induced brain activation are present before clinically measurable cognitive decrements in type 2 diabetes. this is a cross-sectional and longitudinal study to establish diagnostic models based on olfactory function assessments and odor-induced brain activation for cognitive impairment in patients with type 2 diabetes mellitus. the investigators will recruit 200 patients with type 2 diabetes in the outpatient and inpatient departments. health controls will be recruited from the community. at the baseline, clinical information collection, 100g-steamed bread meal test, biochemical measurement, cognitive assessments, olfactory test and functional magnetic resonance imaging(fmri) scan will be conducted for all participants. study duration was 3 years with a follow-up every 18 months. in the longitudinal study, all of the assessments will be repeated to evaluate changes of observational parameters.

Eligibility criteria:
inclusion criteria: * aged 40-75 years * right handedness * possessed over 6-year education * provision of informed consent prior to any study specific procedures * disease duration of t2dm patients \>1 year exclusion criteria: * control participants would be excluded if they had a fasting blood glucose level \>7.0 mmol/l; glucose level\> 7.8 mmol/l after oral glucose tolerance test (ogtt); hba1c\>5.7% * control participants would be excluded if they had a montreal cognitive assessment (moca, beijing edition) score of \< 26 * any acute disease * history of neurologic or psychological illness * abnormal results of thyroid hormones, vitamin b12, and folate * metal implants, unable to complete the mr scanning * partial or complete olfactory dysfunction associated with sinusitis, allergic rhinitis, and deviated nasal septum * pregnant or lactating women * participating in other clinical trials at the same time or within 6 months prior to the start of the trial
thoracic paravertebral block versus iv fentanyl infusion

Conditions: Postoperative Pain

Summary: high-quality analgesia during and following cardiac surgery is infrequently obtained, sternotomy and thoracotomy is associated with significant pain that resulte in hypoventilation, atelectasis, and hypoxemia,pain management is rarley a priority in the immediate postoperative care of these patients, who frequently require mechanical ventilation in an intensive care environment

paravertebral nerve blocks (pvbs) can provide excellent intraoperative anaesthetic and postoperative analgesic conditions with less side effects and fewer contraindications than central neural blocks,bilateral pvb has been successfully used in the thoracic, abdominal, and pelvic regions(12). paravertebral analgesia is produced by placing local anaesthetic (la) alongside the vertebral column, close to the exit of the spinal nerves(13).. traditionally, profound intraoperative analgesia has been provided by using high doses of opioids to suppress hormonal and metabolic stress responses to surgical stimuli. this regimen resulted in improved morbidity and mortality after cardiac surgery(14).

Eligibility criteria:
inclusion criteria: * males and females patients scheduled for elective open heart surgery exclusion criteria: * patients with chest trauma, injuries to peripheries, unstable hemodynamics, sensitivity to local anesthetic drugs, infection at the operation site, renal or hepatic dysfunction, left ventricular dysfunction, coagulation abnormalities and patients on opioids
measure the effects of specific thoracic chiropractic adjustments on blood pressure and pulse rate

Conditions: Hypertension

Summary: the purpose of this randomized controlled trial (rct) is to measure the effects of specific thoracic (t5 to t1) chiropractic adjustments on bp and pr in a larger sample size of both normotensive and hypertensive humans.

objective: previous studies on the effects of chiropractic treatment on blood pressure (bp) and pulse rate (pr) have reported decreases in both systolic and diastolic bp, as well as pr. however, many of those studies have been criticized for various study flaws, and accused of drawing erroneous conclusions, due to small sample size and various methodological concerns. the purpose of this randomized controlled trial (rct) is to measure the effects of specific thoracic (t5 to t1) chiropractic adjustments on bp and pr in a larger sample size of both normotensive and hypertensive humans.

Eligibility criteria:
inclusion criteria: * subjects were invited to participate in accordance with the guidelines for chiropractic quality assurance and practice parameters: proceedings of the mercy center consensus conference, gaithersburg, md, 1993, aspen publishers inc. additionally and specifically for this rct: 1. both male and female subjects age 18 years and older were invited to participate 2. subjects must not be pregnant 3. subjects must not have any recent or current fractures of the arms or legs 4. subjects must not have any visceral or abdominal condition such that being in the prone position would be detrimental to their health 5. subjects must not have any known primary cancers of the spine or spinal column, nor any secondary metastatic process of the spine or spinal column 6. subjects must not be under the influence of drugs or alcohol 7. subjects must not have vertigo or any other imbalance condition 8. subjects must not have any arm or leg prosthetic device 9. subjects must be able to understand spoken and/or written spanish and/or english exclusion criteria:

Keywords: chiropractic blood pressure pulse rate thoracic
epidemiology of sexually transmitted infections and its impact on female infertility

Conditions: Sexually Transmitted Infection

Summary: a longitudinal study to investigate the prevalence of sexually transmitted infections among young women and determine the role of the female genital tract microbiome in fertility


Eligibility criteria:
inclusion criteria: * 18-22 years * informed consent exclusion criteria: * pregnancy * sterilization * not capable of giving informed consent
fertility restoration using autologous mesenchymal stem cells

Conditions: Chronic Endometritis; Uterus; Scar; Uterine Synechiae; Fallopian Tube Obstruction

Summary: treatment of the patients with scarring and adhesions in the uterus resulting from caesarean section or chronic inflammation in the mucosa of the uterus and fallopian tubes and preventing the occurrence of these effects in the future

the aim of the project is to develop a biomedical cell product based on autologous adipose tissue derived mesenchymal stem cells and a biodegradable carrier for highly effective treatment and prevention of scarring and adhesions in the uterus acquired as a result of cesarean section or chronic inflammatory processes in the uterine mucosa and fallopian tubes; to conduct the clinical trials of the biomedical cell product in the treatment of uterus scarring and infertility in women.

Eligibility criteria:
inclusion criteria: * chronic endometritis * postoperative uterus scars * uterine synechia * fallopian tube obstruction * absence of acute inflammation in the uterus exclusion criteria: * patients with genetic diseases of muscle and connective tissue; * patients with malformations of the uterus; * acute and chronic infectious diseases: hiv, mycoplasma infection, hepatitis b and c, syphilis; autoimmune diseases; oncological diseases; continuous hormonal therapy with cytostatics corticosteroids; acute noncommunicable diseases; * mental disorders; * drug or alcohol addiction; * benign tumors of uterus and appendages; * hypersensitivity to any component of the studied biomedical cell product.

Keywords: fertility restoration mesenchymal stem cells
the global prevalence of infections in urology study

Conditions: Hospital Infection; Urinary Tract Infections

Summary: urology departments from all over the world are invited to join the global prevalence study on infections in urology (gpiu-study) and the gpiu prostate biopsy side study. the gpiu study is taking part annually in november since 2003. european urologists were the first group of specialist to register hospital acquired infections on an international level. more than 20.000 patients have been screened and more than 2000 patients are currently listed in this database. why? infectious complications after urological procedures, such as prostate biopsy and increasing antimicrobial resistance are posing significant threats to modern urology the gpiu-study is a combined quality improvement initiative and a scientific study. once the participating departments have filled in the report forms they will get access to statistics showing the accumulated results for all participating hospitals. the participants can anonymously compare their own results with hospitals from all over the world. the gpiu-study application has been designed as an instrument to ongoing follow-up of the development of important factors related to infection on international, national and local levels. take responsibility for the future of urology - join the gpiu-studies! http://gpiu.esiu.org prof. dr. florian m.e. wagenlehner, md, phd clinic for urology, pediatric urology and andrology university clinic giessen, germany gpiu study coordinator prof. truls e. bjerklund johansen, md, phd urology department, oslo university hospital, chairman esiu oslo, no gpiu study coordinator zafer tandogdu university college london (ucl), uk dominic althaus software engineer giessen, ger


Eligibility criteria:
* on the chosen single study day at 08:00 am local time all patients present on the ward of the participating institution are included * the presence of urinary tract infections (uti) according to the cdc definitions during their entire hospital stay are documented and audited and the patients are categorized as having or not having a uti and/or * the presence of surgical site infection (ssi) according to the cdc definitions during their entire hospital stay are documented and audited and the patients are categorized as having or not having a ssi
role of new diagnostic tool in device (icd / pm) associated infections

Conditions: Biomarkers in Device Associated Infections

Summary: infections related to implantable pacemakers or cardioverters defibrillators are sometimes difficult to be diagnosed. diificulties in the diagnosis include a low sensitivity of standard markers of inflammation such as c-reactive protein or white blood cell count and the diagnosis is mainly based on the clinical presentation. the observational dirt-study evaluates if new biomarkers may be more suitable to support a diagnosis of device associated infections than the currently available ones.


Eligibility criteria:
inclusion criteria: * device associated infections exclusion criteria: * malignancy * cytostatic or immunomodulating therapy

Keywords: pacemaker defibrillator infection
associations of lipid measures with premature myocardial infarction: a cross-sectional study

Conditions: Lipid Disorder; Premature Myocardial Infarction

Summary: acute myocardial infarction (ami) is the first cardiovascular cause of death that seriously threatens human health worldwide. its incidence rate and mortality are increasing year by year and becoming younger. according to statistics, the average age of men and women with ami for the first time is 65.6 years old and 72 years old respectively, of which 4%\~10% ami occurred before 45 years old. at present, there is no uniform age threshold for young ami. generally speaking, ami with onset age less than 55 years for men and 65 years for women is called early-onset ami, accounting for 5%\~13% of ami. compared with elderly patients with ami, patients with early onset ami have different risk factors, clinical characteristics and prognosis, such as lower proportion of patients with diabetes and hypertension, more single vessel lesions and rare left main artery involvement, and higher long-term recurrence rate and mortality. although the progress of preventive measures and treatment methods has reduced the hospitalization rate of elderly ami patients, the number of young ami patients in hospital is still rising. therefore, in-depth analysis of the characteristics of risk factors of early onset ami and early intervention are of great significance to reduce the risk of onset and improve long-term prognosis. hyperlipidemia is an independent risk factor for coronary heart disease at all ages, and is more closely related to early onset ami. it is reported that more than 50% of early onset ami patients are accompanied by hyperlipidemia. however, at present, the research on the relationship between blood lipids and early onset ami is limited to the comparison of the level of single lipid component between early onset ami and different control groups, or the comparative analysis of the relationship between a specific lipid component and the risk of early onset ami with young healthy people. there is no research to compare the correlation between various lipid components and the risk of early onset ami. therefore, this study plans to deeply analyze the correlation between different blood lipid components and their ratios and early onset ami, and further analyze which blood lipid indicators are most closely related to early onset ami through large sample clinical research data, taking late onset ami patients as the control, which should be paid early attention to and strictly managed.


Eligibility criteria:
inclusion criteria: * according to the fourth universal definition of myocardial infarction (2018), the clinical diagnosis was acute myocardial infarction (ami), including type 1, 2, 3, 4b and 4c. * complete coronary angiography * complete biochemical and blood lipid tests exclusion criteria: * recurrent ami * the onset of ami exceeds 7 days * continuous taking of lipid-lowering drugs ≥ 5 days * patients with missing data